Targeting the androgen receptor with steroid conjugates

Paul M. Levine, Michael J. Garabedian, Kent Kirshenbaum

Research output: Contribution to journalArticle

Abstract

The androgen receptor (AR) is a major therapeutic target in prostate cancer pharmacology. Progression of prostate cancer has been linked to elevated expression of AR in malignant tissue, suggesting that AR plays a central role in prostate cancer cell biology. Potent therapeutic agents can be precisely crafted to specifically target AR, potentially averting systemic toxicities associated with nonspecific chemotherapies. In this review, we describe various strategies to generate steroid conjugates that can selectively engage AR with high potency. Analogies to recent developments in nonsteroidal conjugates targeting AR are also evaluated. Particular focus is placed on potential applications in AR pharmacology. The review culminates with a description of future prospects for targeting AR.

Original languageEnglish (US)
Pages (from-to)8224-8237
Number of pages14
JournalJournal of Medicinal Chemistry
Volume57
Issue number20
DOIs
StatePublished - Oct 23 2014

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Fingerprint Dive into the research topics of 'Targeting the androgen receptor with steroid conjugates'. Together they form a unique fingerprint.

  • Cite this